本文へスキップ
Likelier

行動 vs. 不行動:各選択の数値

2025年のはしか再流行に際し、成人としてMMR(麻疹・流行性耳下腺炎・風疹)の抗体検査や追加接種を受けるか、それとも見送るか?

行動した場合

成人用MMRの抗体検査・追加接種を受ける

直接の測定はありません

行動しなかった場合

検査・追加接種を受けず子ども時代の免疫に頼る

6.0%

少なくとも1つの数値は間接的な推定値であり、実際に測定した後悔の割合ではありません。各数値の算出方法は下に記載しています。


健康

最終確認 2026-06-13

証拠の質 4.1/5

8次元のレビュー評価。基準は 品質ルーブリック 。各次元は1〜5で評価。

D1 出典の検証
5/5
D2 出典の権威性と独立性
5/5
D3 後悔率の正確性
3/5
D4 出典の比較可能性
3/5
D5 ギロヴィッチ・パターン
4/5
D6 文章の質
4/5
D7 注意事項の完全性
4/5
D8 サンプルの質
5/5
平均 4.1/5
An abstract editorial symbol evoking "Adult MMR booster vs. skip", muted two-tone palette, flat vector.
間接データ:この決断については、少なくとも1つの数値が、後悔を直接尋ねた調査ではなく、結果、満足度、意向といった間接的な指標、または編集部による推定に基づいています。各数値の算出方法は、下の各選択肢の注記に記載しています。

行動した場合

成人用MMRの抗体検査・追加接種を受ける

直接の測定はありません

この選択肢について数値を示す出典がないため、数値は表示していません。

US adults who seek an MMR titer or a precautionary MMR dose (1963-67 killed-vaccine cohort, healthcare personnel, immunocompromised contacts) during the 2025 resurgence

Per dose administered

行動しなかった場合

検査・追加接種を受けず子ども時代の免疫に頼る

6.0%

~6% — proxy: share of a US healthcare-worker serosurvey lacking a measles immunity marker (seronegative + equivocal); an upper bound on who carries an immunity gap, not a measured regret rate

US adults in the named higher-risk cohorts (1963-67 killed-vaccine recipients, healthcare personnel, immunocompromised) who skip serologic check or revaccination during the 2025 resurgence

Cross-sectional immunity gap during the 2025 resurgence

各選択の数値(何を測ったかはページに明記)

関連する決断

意味的に類似する決断 — 同じ領域、異なるトレードオフ。

健康

疑わしいほくろの切除 対 経過観察

各選択の数値(何を測ったかはページに明記)

健康

無症状の親知らず抜歯 対 経過観察

各選択の数値(何を測ったかはページに明記)

健康

LASIK眼科手術

各選択の数値(何を測ったかはページに明記)

lifestyle

タトゥー

各選択の数値(何を測ったかはページに明記)

健康

ボディピアス

各選択の数値(何を測ったかはページに明記)

健康

DNA祖先・健康テスト vs. 受けない

各選択の数値(何を測ったかはページに明記)

健康

事前指示書の作成タイミング

各選択の数値(何を測ったかはページに明記)

健康

リスク低減乳房切除 対 監視

各選択の数値(何を測ったかはページに明記)

No survey asks adults whether they regret getting, or skipping, a measles booster during the 2025 resurgence. This pair is a proxy. The action side is anchored on the probability of a serious adverse event from the shot itself, and the inaction side on the share of the relevant cohort that carries no measurable measles immunity. Neither number is a regret rate; both are stand-ins.

Anaphylaxis after an MMR-containing vaccine was reported to VAERS at 0.6 per million doses over 1990 to 2016, and the CDC’s Vaccine Information Statement describes a serious reaction as a “very remote chance.” The common outcomes are a sore arm, a brief fever and a mild rash.

The inaction side is where the cohorts in the question matter. A US healthcare-worker serosurvey found 4% seronegative and 2% equivocal for measles IgG — a roughly 6% immunity gap — and a 2025 meta-analysis of 23,236 vaccinated people pooled seropositivity at 87.8%, falling to 84.3% among single-dose recipients. The 1963-67 killed-vaccine cohort is a separate, smaller group that ACIP explicitly tells to revaccinate, because the inactivated product conferred little durable protection. The catch is that an immunity gap is not the same as realized regret: with 2,289 confirmed US cases in 2025 against a population of roughly 340 million, the national attack rate stayed near 0.0007%, so most seronegative adults were never exposed at all. What gives the gap its weight is the severity tail — 11% of 2025 cases were hospitalized and there were deaths — so the rare intersection of “no immunity” and “exposed” is consequential.

出典: 行動

根拠台帳

以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。

1/2 件の出典が引用元と一字一句一致することを独立して検証済み

  1. [1] Journal of Allergy and Clinical Immunology / NCBI PMC — Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990–2016 検証済み
    Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990–2016
    統計値
    MMR-containing vaccine anaphylaxis reporting rate of 0.6 per 1 million doses distributed (overall vaccine rate 1.3 per million).
    抜粋
    “The estimated rate of anaphylaxis reported to VAERS during 1990 to 2016 after MMR was 0.6 per 1 million doses distributed.”
    出典データ
    2019-01-01
    アクセス日
    2026-06-13
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    Anaphylaxis is the canonical serious adverse event of MMR. 0.6 per 1,000,000 doses = 6e-7. The action regret rate is set conservatively above that floor (1e-5) to absorb other rare serious events (febrile seizure, transient thrombocytopenia) the VIS lists. The dominant 'downside' of acting for an already-immune adult is a redundant dose, which yields peace of mind rather than regret, so it is not counted as regret. This is the matched-severity proxy: action's regret-worthy outcome is a serious AE, not 'the shot turned out unnecessary'.
  2. [2] U.S. Centers for Disease Control and Prevention — MMR Vaccine Information Statement (VIS)
    MMR Vaccine Information Statement (VIS)
    統計値
    Serious adverse events from MMR are characterized as a very remote chance; common effects are minor (sore arm, fever, mild rash).
    抜粋
    “As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.”
    出典データ
    2025-01-31
    アクセス日
    2026-06-13
    計算過程
    Qualitative confirmation that the action side's serious downside is 'very remote.' Establishes that the regret-worthy outcome of acting is rare and severe (an AE), distinct from the common, non-regret outcome of a redundant-but-protective dose. No numeric rate on this page; the numeric anchor is PMC6580415.

出典: 不作為

根拠台帳

以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。

3/6 件の出典が引用元と一字一句一致することを独立して検証済み

  1. [1] Infection Control and Hospital Epidemiology (PubMed) — Measles immunity in a population of healthcare workers 検証済み
    Measles immunity in a population of healthcare workers
    統計値
    Among 2,473 US healthcare workers tested for anti-measles IgG, 4% were seronegative and 2% equivocal — a ~6% immunity gap.
    抜粋
    “Ninety-three workers (4%) were seronegative, and 56 (2%) were equivocal.”
    出典データ
    1994-01-01
    アクセス日
    2026-06-13
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    Population-matched anchor: US healthcare workers, one of the named higher-risk cohorts. Seronegative (4%) + equivocal (2%) = 6% lacking a measles immunity marker → inaction proxy 0.06. This is an immunity-gap upper bound, not a realized-regret rate: most seronegative people are never exposed (2025 national attack rate ~ 2,289 / ~340M ~ 0.0007%). The proxy measures who is even eligible for potential regret if exposed.
  2. [2] eClinicalMedicine (The Lancet Discovery Science) — Measles seropositivity in previously vaccinated individuals: a systematic review and meta-analysis
    Measles seropositivity in previously vaccinated individuals: a systematic review and meta-analysis
    統計値
    Pooled seropositivity among vaccinated individuals was 87.8% (so ~12.2% seronegative); single-dose recipients 84.3% seropositive (~15.7% seronegative), across 23,236 individuals from 10 countries.
    抜粋
    “Pooled seropositivity was 87·8% (95% CI, 83·9%–91·2%) across 23,236 vaccinated individuals”
    出典データ
    2025-01-01
    アクセス日
    2026-06-13
    計算過程
    Current (2025) pooled anchor confirming waning: ~12% of vaccinated adults are below seropositivity thresholds, rising to ~16% for single-dose recipients. Verified verbatim via Playwright (the Lancet page blocks plain fetching). Used to frame the spread; the 6% HCW figure is kept as the population-matched headline rather than the 12-16% pooled (mixed-country, assay-threshold) number to avoid overstating realized susceptibility.
  3. [3] U.S. Centers for Disease Control and Prevention — Measles Vaccination for Specific Groups
    Measles Vaccination for Specific Groups
    統計値
    ACIP recommends revaccinating recipients of killed/inactivated or unknown-type measles vaccine from 1963-1967; healthcare personnel without presumptive immunity need 2 doses.
    抜粋
    “The ACIP recommends re-vaccinating anyone who received measles vaccine of unknown type, inactivated measles vaccine, or further attenuated measles vaccine accompanied by immunoglobulin or high-titer measles immune globulin (no longer available in the United States) during these years with 1 or 2 doses.”
    出典データ
    2024-07-15
    アクセス日
    2026-06-13
    計算過程
    Establishes that the 1963-67 killed-vaccine cohort is functionally unprotected per ACIP and explicitly advised to revaccinate — the qualitative basis for why skipping carries downside for this cohort. This cohort is <5% of adults and overlaps the pre-1957 presumed-immune group, so it informs but does not set the numeric anchor.
  4. [4] CDC MMWR / NCBI PMC — Measles Update — United States, January 1–April 17, 2025 検証済み
    Measles Update — United States, January 1–April 17, 2025
    統計値
    Of 800 confirmed 2025 cases through April 17, 96% were unvaccinated or unknown status, 11% hospitalized, 3 deaths.
    抜粋
    “Overall, 771 (96%) patients have been unvaccinated or had unknown vaccination status”
    出典データ
    2025-04-24
    アクセス日
    2026-06-13
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    Establishes the severity tail that makes the immunity gap consequential: 11% of measles cases hospitalized, 3 deaths in the period, 96% of cases in the unvaccinated/unknown. The realized harm to someone in the immunity gap who is exposed is severe; this is what gives the inaction proxy its weight.
  5. [5] U.S. Centers for Disease Control and Prevention — Measles Cases and Outbreaks — 2025 Data Summary 検証済み
    Measles Cases and Outbreaks — 2025 Data Summary
    統計値
    Full-year 2025: 2,289 confirmed US measles cases
    抜粋
    “For the full year of 2025, a total of 2,289 confirmed* measles cases were reported in the United States.”
    出典データ
    2026-06-12
    アクセス日
    2026-11-04
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    Sets the exposure backdrop: 2,289 cases / ~340M US population ~ 0.0007% national attack rate. This is why the 6% immunity-gap proxy is explicitly an upper bound on potential regret, not realized regret — exposure remained geographically concentrated and rare nationally even in 2025.
  6. [6] The Texas Tribune — Texas measles victim's parents stand by decision to not vaccinate
    Texas measles victim's parents stand by decision to not vaccinate
    統計値
    After their unvaccinated 6-year-old daughter died of measles in Gaines County, Texas in February 2025, the parents said in a recorded statement that the death did not change their opposition to the MMR vaccine.
    抜粋
    “"“We would absolutely not take the MMR,” the mother said in English, referring to the measles-mumps-rubella vaccination children typically receive before attending school. She said her stance on vaccination has not changed after her daughter’s death." ”
    出典データ
    2025-03-20
    アクセス日
    2026-07-03
    計算過程
    Illustrative real-world counterpoint, not a numeric input to the 0.06 inaction proxy: a parent's decision about a child's routine MMR dose amid a measles death is a different population and decision from the adult titer/booster question this entry covers, and one family's account is not a survey. Cited to support the body-text point that documented post-outbreak reactions do not uniformly run toward regretting non-vaccination.

注意事項

Proxy figures only: there is no direct "regret getting/skipping an MMR booster" survey; both rates are stand-ins. The inaction rate (6%) is the share of a US healthcare-worker serosurvey lacking an immunity marker (seronegative + equivocal), i.e. an upper bound on who is even eligible for regret, NOT a measured regret rate — most seronegative people are never exposed (2025 national attack rate ~0.0007%). The susceptibility spread is wide and assay-dependent: 6% (US HCW IgG), 12.2% (2025 pooled meta-analysis), up to ~37.6% in one Olmsted County, MN commercial-assay study whose high figure is largely a below-titer-threshold artifact (titer below cutoff does not equal susceptible, because anamnestic memory-B-cell immunity is not captured) and is therefore excluded from the anchor. The 1963-67 killed-vaccine cohort is <5% of adults and overlaps the pre-1957 presumed-immune group, so it is a qualitative ACIP-revaccinate flag rather than the numeric anchor. The action anaphylaxis figure (0.6/million) is a passive-surveillance VAERS reporting rate, not a measured incidence. The meta-analysis pools 10 countries, not US-only. CDC publishes immunity and case data, not regret; this entry should not be read as advice to get or skip a dose.

生データ: /api/decisions.json

このデバイスで最近見た項目